OM was the most common entity when reclassified by a novel clinicoserologic classification, 74% of total individuals. probably the most and the second most frequent entities. Overlap myositis was the major entity of IIM, and the rate of recurrence of PM was significantly lower when applying clinicoserologic classification criteria. Sixty-nine (63.9%) individuals had one or more MSA, and 61 (56.5%) individuals had one or more MAA. Interstitial lung disease was closely associated with anti-MDA5 and anti-ARS, and DM-specific skin lesions were regularly observed in individuals with anti-TIF1, anti-SRP, and anti-MDA5. Summary The clinicoserologic criteria based on MSA/MAA positivity could reflect more precise medical features of IIM. Establishment of a laboratory system regularly available to display for MSA/MAA status will be beneficial to provide precise analysis and proper management of IIM individuals. ideals of 0.05 were considered statistically significant. RESULTS Demographics and medical characteristics of the individuals The mean age at analysis of IIM was 50.613.9 years; 79 (73.1%) individuals were female. The mean interval between medical onset and myositis analysis was 16.3 months. The mean period of follow-up after myositis analysis was 5.7 years. Eighty (74.1%) individuals had proximal muscle mass weakness. The elevation of muscle mass enzyme was mentioned in 96 (88.9%) individuals, and the mean CK level was 3459.64511.1 U/L. The medical characteristics of the individuals are summarized in Table 1. ILD was recorded in 57 individuals, comprising 52.8% of all individuals, 52.2% of the PM group, and 52.6% of the DM group. Fourteen (13%) malignancies were diagnosed Table 1 Medical and Demographic Characteristics of the Study Patients value /th /thead Age at HA130 analysis (yr)52.912.947.814.161.815.950.613.90.034Sex lover (F:M)29:1745:125:079:290.074Disease period (yr)6.194.195.474.663.402.515.694.400.354Immunosuppressant user40 (87.0)47 (82.5)5 (100.0)92 (85.2)0.525Steroid dosage* (mg)246.1420.9217.4384.4285.0539.9230.9402.40.973Clinical manifestation?Arthritis10 (21.7)16 (28.1)1 (20.0)27 (25.0)0.799?Raynaud trend6 (13.0)7 (12.3)1 (20.0)14 (13.0) 0.999?Dysphagia5 (10.9)11 (19.3)0 (0.0)16 (14.8)0.349?ILD24 (52.2)30 (52.6)3 (60.0)57 (52.8) 0.999?Malignancy3 (6.5)11 (19.3)0 (0.0)14 (13.0)0.301 Open in a separate window PM, polymyositis; IMNM, immune mediated necrotizing myositis; HA130 DM, dermatomyositis; ADM, amyopathic dermatomyositis; ILD, interstitial lung disease. Ideals are presented like a meanstandard deviation or total n (%). *The highest dose of steroid used in the 1st treatment. Classification of idiopathic IIM Of all 108 individuals, only 79 individuals who experienced undergone biopsy were reclassified. The distribution of subgroups of IIM using the 2017 EULAR/ACR criteria differed strikingly from those using the novel clinicoserologic criteria (Fig. 1). At myositis analysis, relating to 2004 ENMC criteria, 35 certain PM, one IMNM, 42 certain DM, and one DM sine dermatitis were seen. According to the ENMC criteria and 2017 EULAR/ACR criteria, DM was the most frequent entity (n=42, 53.2%). In impressive contrast, using the new clinicoserologic classification criteria, OM was the most common entity (n=60, 75.9%), and only 8 of 42 individuals diagnosed with DM from FAM162A the ENMC classification criteria were still classified as genuine vintage DM (n=8, 10.1%). Also, 10 instances (12.7%) HA130 were reclassified while pure PM by new classification criteria. This shown that previous criteria could not reflect the overlap medical features of IIM. Open in a separate windowpane Fig. 1 Distribution of 79 individuals with myositis at analysis relating to three classifications for idiopathic inflammatory myopathies. PM, polymyositis; DM, dermatomyositis; IMNM, immune mediated necrotizing myositis; OM, overlap myositis. Autoantibody profiles of reclassified organizations by novel clinicoserologic criteria Sixty-nine (63.9%) individuals had one or more MSA, and 61 (56.5%) individuals had one or more MAA among all 108 individuals. The rate of recurrence of autoantibodies in the reclassified organizations according to fresh clinicoserologic criteria are demonstrated in Table 2. In 79 individuals, ANA was positive in 45 (57.0%) individuals. Forty-four (55.7%) individuals had one or more MSA (including Anti-Jo-1, OJ, EJ, PL7, PL12, SRP, MDA5, Mi2, TIF1-r, SAE), and 42 (53.2%) individuals had one or more MAA (including Anti-Ro52, Ku, PM-Scl). Anti-Ro52, one of the MAAs, was most frequently observed (34, 43.0%). After that, the frequencies of antibodies were as follows: anti-ARS (17,.